Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;2(1):25-7.
doi: 10.4103/0976-7800.83263.

A randomized trial of vaginal misoprostol for cervical priming before hysteroscopy in postmenopausal women

Anita Kant  1 , Divyakumar, Usha Priyambada
Affiliations

A randomized trial of vaginal misoprostol for cervical priming before hysteroscopy in postmenopausal women

Anita Kant et al. J Midlife Health. 2011 Jan.

Abstract

Objective: To perform hysteroscopy the cervix needs to be dilated and in nullipara and postmenopausal women this is sometimes difficult. Well-known, entry-related complications during hysteroscopy include cervical tear, creation of false tract, bleeding, uterine perforation, scarring, and subsequent anatomical stenosis.

Materials and methods: This study was done to investigate the priming effect of vaginal misoprostol on cervical dilatation in postmenopausal women, before hysteroscopy, to prevent such complications. Two hundred micrograms of misoprostol was inserted into the vagina at least 12 hours before the procedure and the control group did not receive any cervical priming agent. Pre-procedural dilatation, additional dilatation required, and time taken for dilatation was noted in each case.

Observations: The study showed a significant difference between the study group (7.7 ± 1.7 mm) and the control group (4.5 ± 1.8 mm) in terms of pre-procedural cervical width and the number of women requiring a dditional dilatation (7 / 25 versus 22 / 25), and hence, the time required for dilatation (4.7 ± 8 seconds versus 20.6 ± 9.3 seconds).

Conclusion: The pre-procedural cervical width was significantly more in the study group as compared to that in the control group. We found significant differences between the study and control groups with respect to the number of women who required cervical dilatation. To conclude, this study helps derive a conclusion that vaginal misoprostol as a cervical priming agent in postmenopausal women appears to be safe, effective, and inexpensive, with mild side effects.

Keywords: Cervical priming; hysteroscopy; misoprostol.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Ngai SW, Tang OS, Lao T, Ho PC, Ma HK. Oral misoprostol versus placebo for cervical dilatation before vacum aspiration in first trimester pregnancy. Hum Reprod. 1995;5:1220–2. - PubMed
    1. Ngai WN, Chan YM, Liu KL, Ho PC. Oral misoprostol for cervical priming in nonpregnant women. Hum Reprod. 1997;12:2373–5. - PubMed
    1. Goldberg A, Greenberg M, Darney P. Misoprostol and pregnancy. N Engl J Med. 2001;344:38–45. - PubMed
    1. Meckstroth KR, Darneyy PD. Prostaglandins for the first trimester termination. Best Pract Res. 2003;3:475–83. - PubMed
    1. Hofmey GJ, Gulmrzoglu AM. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database SystRev. 2003;1:CD000941. - PubMed